Screener
Neurocrine Biosciences NBIX Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Neurocrine Biosciences in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The source filing: Neurocrine Biosciences’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000914475-26-000026
| (in millions, except per share data) | March 31,2026 | December 31,2025 |
|---|---|---|
| Accounts payable and accrued liabilities | $773.0 | $674.3 |
| Other current liabilities | 58.7 | 69.1 |
| Total current liabilities | 831.7 | 743.4 |
| Noncurrent operating lease liabilities | 406.2 | 415.3 |
| Other noncurrent liabilities | 260.9 | 219.7 |
| Total liabilities | 1,498.8 | 1,378.4 |
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 5.0 shares authorized; no shares issued and outstanding | — | — |
Item 1. Financial Statements
FAQ
- What is Neurocrine Biosciences's operating lease liabilities?
- Neurocrine Biosciences (NBIX) reported operating lease liabilities of $406.2M in Q1 2026.
- How has Neurocrine Biosciences's operating lease liabilities changed year-over-year?
- Neurocrine Biosciences's operating lease liabilities decreased by 9.2% year-over-year, from $447.5M to $406.2M.
- What is the long-term trend for Neurocrine Biosciences's operating lease liabilities?
- Over 5 years (2020 to 2025), Neurocrine Biosciences's operating lease liabilities has grown at a 34.5% compound annual growth rate (CAGR), from $94.4M to $415.3M.
- What does operating lease liabilities mean?
- Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.
Ask your AI about Neurocrine Biosciences's operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude